Scholarlink

<p>The toxicity of drugs to normal cells exhibits a significant risk to human health. Currently, researchers worldwide are striving to develop custom-designed drugs that have reduced toxicity and fewer side effects. Polymeric nanoparticles have drawn interest in being a suitable anticancer drug carrier and molecular visualization. Paclitaxel (PTX) has great potential as an anticancer drug though it suffers from poor aqueous solubility, limiting its therapeutic efficacy. This study investigated a novel β-cyclodextrin (β-CD) inclusion complex for enhanced PTX delivery against triple-negative human breast cancer (aka. MDA-MB-231). Molecular docking simulations indicated the strongest binding between β-CD and PTX compared to α-CD and γ-CD. The 1:2 molar ratio of β-CD to PTX achieved the highest entrapment efficiency (over 95.23%) and improved PTX solubility. Characterization techniques confirmed the successful formation of inclusion complex PTX-β-CD (IC). The IC exhibited critical cytotoxicity against MDA-MB-231. It diminishes colony formation and hampers the migration of cells. Evaluation of cellular morphology by apoptosis assays demonstrated the formulations’ impact on both the cytoskeleton and cytotoxicity of MDA-MB-231, potentially inducing apoptosis. The synthesized IC shows significant potential for pharmaceutical development.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

β-cyclodextrin inclusion complex as a potent delivery system for enhanced cytotoxicity of paclitaxel in triple-negative breast cancer cells

  • 期刊论文

  • 发表日期：

    2025年1月25日

查看全文
  • Kamini Velhal,
  • Parvindar Sah,
  • Smitali Patil,
  • Rajesh Raut,
  • Ramesh Yamgar,
  • Jaya Lakkakula,
  • Imran Uddin

摘要

The toxicity of drugs to normal cells exhibits a significant risk to human health. Currently, researchers worldwide are striving to develop custom-designed drugs that have reduced toxicity and fewer side effects. Polymeric nanoparticles have drawn interest in being a suitable anticancer drug carrier and molecular visualization. Paclitaxel (PTX) has great potential as an anticancer drug though it suffers from poor aqueous solubility, limiting its therapeutic efficacy. This study investigated a novel β-cyclodextrin (β-CD) inclusion complex for enhanced PTX delivery against triple-negative human breast cancer (aka. MDA-MB-231). Molecular docking simulations indicated the strongest binding between β-CD and PTX compared to α-CD and γ-CD. The 1:2 molar ratio of β-CD to PTX achieved the highest entrapment efficiency (over 95.23%) and improved PTX solubility. Characterization techniques confirmed the successful formation of inclusion complex PTX-β-CD (IC). The IC exhibited critical cytotoxicity against MDA-MB-231. It diminishes colony formation and hampers the migration of cells. Evaluation of cellular morphology by apoptosis assays demonstrated the formulations’ impact on both the cytoskeleton and cytotoxicity of MDA-MB-231, potentially inducing apoptosis. The synthesized IC shows significant potential for pharmaceutical development.